About the Authors
Paul F. Glenn Laboratories for the Biological Mechanisms of Aging, Department of Pathology, Harvard Medical School, Boston, Massachusetts, United States of America
DAS is a founder, director, share holder, and scientific consultant to Sirtris Pharmaceuticals, a company whose goal is to develop sirtuin-activating molecules to treat disease.
OM, DWL, and DAS conceived and designed the experiments. OM, DWL, and KDK performed the experiments. All authors analyzed the data. OM, DWL, and DAS contributed reagents/materials/analysis tools and wrote the paper.